Rhelion Life Sciences Corp. TRUFF
Set alert
0.01 USD 0.00 -17.65%
At close · Oct 30
0.014 Day range 0.017
0.005 52-week range 0.043
- YTD
- -12.50%
- 1 year
- -36.36%
- Open
- 0.017
- Prev close
- 0.017
- Mkt cap
- 8.60M
- Vol
- 246.28K
- Avg vol
- 114.59K
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 0.014
- High
- 0.017
6M chart
Signals (51)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bullish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| MACD: Buy Signal | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 13, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 13, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | May 12, 2026 | 5 months ago |
News
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression
- Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New Canadian Patent, Extending the Broadest Natural Psilocybin Patent Estate
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Delivers PEX010 to Bruyere Health Research Institute's Phase 3 Trial of Microdose Psilocybin in Palliative Care
- Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin
- Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy
Your note
Sign in to keep a note on TRUFF — it syncs with the Stock Master app.